Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial
ARROW Trial team, ARROW Trial team
Abstract
Background: No trials have investigated routine laboratory monitoring for children with HIV, nor four-drug induction strategies to increase durability of first-line antiretroviral therapy (ART).
Methods: In this open-label parallel-group trial, Ugandan and Zimbabwean children or adolescents with HIV, aged 3 months to 17 years and eligible for ART, were randomly assigned in a factorial design. Randomisation was to either clinically driven monitoring or routine laboratory and clinical monitoring for toxicity (haematology and biochemistry) and efficacy (CD4 cell counts; non-inferiority monitoring randomisation); and simultaneously to standard three-drug or to four-drug induction first-line ART, in three groups: three-drug treatment (non-nucleoside reverse transcriptase inhibitor [NNRTI], lamivudine, abacavir; group A) versus four-drug induction (NNRTI, lamivudine, abacavir, zidovudine; groups B and C), decreasing after week 36 to three-drug NNRTI, lamivudine, plus abacavir (group B) or lamivudine, abacavir, plus zidovudine (group C; superiority ART-strategy randomisation). For patients assigned to routine laboratory monitoring, results were returned every 12 weeks to clinicians; for clinically driven monitoring, toxicity results were only returned for requested clinical reasons or if grade 4. Children switched to second-line ART for WHO stage 3 or 4 events or (routine laboratory monitoring only) age-dependent WHO CD4 criteria. Randomisation used computer-generated sequentially numbered tables incorporated securely within the database. Primary efficacy endpoints were new WHO stage 4 events or death for monitoring and change in CD4 percentage at 72 and 144 weeks for ART-strategy randomisations; the co-primary toxicity endpoint was grade 3 or 4 adverse events. Analysis was by intention to treat. This trial is registered, ISRCTN24791884.
Findings: 1206 children were randomly assigned to clinically driven (n=606) versus routine laboratory monitoring (n=600), and groups A (n=397), B (n=404), and C (n=405). 47 (8%) children on clinically driven monitoring versus 39 (7%) on routine laboratory monitoring had a new WHO stage 4 event or died (hazard ratio [HR] 1·13, 95% CI 0·73-1·73, p=0·59; non-inferiority criterion met). However, in years 2-5, rates were higher in children on clinically driven monitoring (1·3 vs 0·4 per 100 child-years, difference 0·99, 0·37-1·60, p=0·002). One or more grade 3 or 4 adverse events occurred in 283 (47%) children on clinically driven versus 282 (47%) on routine laboratory monitoring (HR 0·98, 0·83-1·16, p=0·83). Mean CD4 percentage change did not differ between ART groups at week 72 (16·5% [SD 8·6] vs 17·1% [8·5] vs 17·3% [8·0], p=0·33) or week 144 (p=0·69), but four-drug groups (B, C) were superior to three-drug group A at week 36 (12·4% [7·2] vs 14·1% [7·1] vs 14·6% [7·3], p<0·0001). Excess grade 3 or 4 events in groups B (one or more events reported by 157 [40%] children in A, 190 [47%] in B; HR [B:A] 1·32, 1·07-1·63) and C (218 [54%] children in C; HR [C:A] 1·58, 1·29-1·94; global p=0·0001) were driven by asymptomatic neutropenia in zidovudine-containing groups (B, C; 86 group A, 133 group B, 184 group C), but resulted in drug substitutions in only zero versus two versus four children, respectively.
Interpretation: NNRTI plus NRTI-based three-drug or four-drug ART can be given across childhood without routine toxicity monitoring; CD4 monitoring provided clinical benefit after the first year on ART, but event rates were very low and long-term survival high, suggesting ART rollout should take priority. CD4 benefits from four-drug induction were not durable, but three-NRTI long-term maintenance was immunologically and clinically similar to NNRTI-based ART and could be valuable during tuberculosis co-treatment.
Funding: UK Medical Research Council, the UK Department for International Development; drugs donated and viral load assays funded by ViiV Healthcare and GlaxoSmithKline.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Figures
References
- Gilks CF, Crowley S, Ekpini R. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006;368:505–510.
- Institute for Health Metrics and Evaluation Financing global health 2011: continued growth as MDG deadline approaches. (accessed Oct 25, 2012).
- UNAIDS . World AIDS Day report 2012. UNAIDS; Geneva: 2012.
- Abongomera G, Namata H, Nkhata M, et al. Lablite: baseline mapping survey of decentralised ART service provision in Malawi, Uganda and Zimbabwe. XIX International AIDS Conference; Washington DC, USA; July 22–27, 2012; abstr LBPE572012.
- DART Trial Team Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2010;375:123–131.
- Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. PHPT-3: a randomized clinical trial comparing CD4 vs viral load ART monitoring/switching strategies in Thailand. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA; Feb 27–March 2, 2011; abstr 44.
- Laurent C, Kouanfack C, Laborde-Balen G. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis. 2011;11:825–833.
- Mermin J, Ekwaru JP, Were W. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ. 2011;343:d6792.
- HIV Paediatric Prognostic Markers Collaborative Study Group (HPPMCS) Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet. 2003;362:1605–1611.
- HIV Paediatric Prognostic Markers Collaborative Study Group (HPPMCS) Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS. 2006;20:1289–1294.
- Cross Continents Collaboration for Kids (3Cs4kids) Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS. 2008;22:97–105.
- Bartlett JA, Fath MJ, Demasi R. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS. 2006;20:2051–2064.
- van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis. 2002;2:93–102.
- Judd A. Early antiretroviral therapy in HIV-1-infected infants, 1996–2008: treatment response and duration of first-line regimens. AIDS. 2011;25:2279–2287.
- WHO . Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. World Health Organization; Geneva: 2006.
- Ssali F, Stohr W, Munderi P. Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther. 2006;11:741–749.
- National Institutes of Health Division of AIDS . Division of AIDS table for grading the severity of adverse events. National Institute of Allergy and Infectious Diseases; Bethesda, MD: 2004. (clarification 2009).
- National Institutes of Health Division of Microbiology and Infectious Diseases (DMID) pediatric toxicity tables. (accessed Feb 11, 2013).
- Kasirye P, Kendall L, Adkison KK. Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. Clin Pharmacol Ther. 2012;91:272–280.
- Musiime V, Kendall L, Bakeera-Kitaka S. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. Antivir Ther. 2010;15:1115–1124.
- WHO . Annex E: prescribing information and weight-based dosing of available ARV formulations for infants and children. World Health Organization; Geneva: 2010.
- International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use . Clinical safety data management: definitions and standards for expedited reporting (E2A) European Medicines Agency; London: 1994.
- Paediatric European Network for the Treatment of AIDS Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet. 2002;359:733–740.
- Wade AM, Ades AE. Age-related reference ranges: significance tests for models and confidence intervals for centiles. Stat Med. 1994;13:2359–2367.
- Medina Lara A, Kigozi J, Amurwon J. Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe. PloS One. 2012;7:e33672.
- Violari A, Cotton M, Otwombe K, et al. Does early initiation of ART in infants affect virologic and resistance outcomes? Data from the CHER trial after 6 years of follow up. HIV11 Congress; Glasgow, UK; Nov 11–14; abstr 0224.
- Green H, Gibb DM, Walker AS. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS. 2007;21:947–955.
- Violari A, Lindsey JC, Hughes MD. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med. 2012;366:2380–2389.
- Prendergast AJ, Penazzato M, Cotton M. Treatment of young children with HIV infection: using evidence to inform policymakers. PLoS Med. 2012;9:e1001273.
- The PENPACT-1 (PENTA 9/PACTG 390) Study Team First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis. 2011;11:273–283.
- Mulenga V, Cook A, Walker AS. Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination “baby pills” in Zambia: a randomized controlled trial. Clin Infect Dis. 2011;51:1081–1089.
- Nahirya-Ntege P, Musiime V, Naidoo B. Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy. Pediatr Infect Dis J. 2010;30:535–537.
- Oudijk JM, McIlleron H, Mulenga V. Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. AIDS. 2012;26:1523–1528.
- Ren Y, Nuttall JJ, Egbers C. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2008;47:566–569.
- Munderi P, Walker AS, Kityo C. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. HIV Med. 2010;11:334–344.
- Musiime V, Kaudha E, Kayiwa J. Antiretroviral drug resistance profiles and response to second-line therapy among HIV-1 infected Ugandan children. AIDS Res Hum Retroviruses. 2013 published online Jan 11.
- Walker AS, Prendergast AJ, Mugyenyi P. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis. 2012;55:1707–1718.
- Berkley JA, Bejon P, Mwangi T. HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria. Clin Infect Dis. 2009;49:336–343.
- Walker AS, Gibb DM. Monitoring of highly active antiretroviral therapy in HIV infection. Curr Opin Infect Dis. 2011;24:27–33.
- Gilks CF, Walker AS, Munderi P, et al. A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria. PloS One (in press).
Source: PubMed